HealthEdge-backed Legacy-Xspire completes acquisition of Zontivity distribution

The product will be marketed under Legacy's subsidiary Xspire Pharma. 

HealthEdge Investment Partners-backed Legacy-Xspire Holdings completed the acquisition of US and Canadian distribution rights for Zontivity from New American Therapeutics. The product will be marketed under Legacy’s subsidiary Xspire Pharma.

Press Release

Legacy-Xspire Holdings, LLC (“Legacy”), a portfolio company of HealthEdge Investment Partners, LLC (“HealthEdge”) announced today that it has completed the acquisition of the US and Canadian distribution rights for ZONTIVITY® (Vorapaxar Sulfate) from New American Therapeutics, LLC. The product will be marketed under Legacy’s wholly-owned subsidiary Xspire Pharma, LLC.

ZONTIVITY is the first product acquisition to expand Legacy’s therapeutic offerings. According to Legacy’s Acting-CEO Robert Cunard, “We are pleased to complete the acquisition of ZONTIVITY. Formally commercialized by Merck & Co. and Aralez Pharmaceuticals, the franchise offers a unique opportunity to leverage Legacy’s targeted sales and marketing strategy to continue to bring a much-needed medication to the market. The product will serve as a foundational element in Legacy’s portfolio and geographic expansion.”

Mike Anderson, CEO of New American Therapeutics said, “We are excited that Legacy will be promoting ZONTIVITY and using the product as a cornerstone in building its pharmaceutical business.”

ZONTIVITY is a prescription medicine used to treat people who have had a heart attack or reduced blood flow in their legs (peripheral artery disease). ZONTIVITY is used with aspirin and/or clopidogrel to lower your chance of having another serious problem with your heart or blood vessels, such as heart attack, stroke, or death. Learn more at

About Legacy-Xspire Holdings
Legacy-Xspire Holdings, LLC, which consists of Wraser Pharmaceuticals and Xspire Pharma, is a unique pharmaceutical company that focuses on proprietary physician-driven brands and high-value late lifecycle generics. Legacy continues to seek opportunities to leverage its sales professionals and the operational expertise of its diverse group of seasoned pharmaceutical experts.

About HealthEdge Investment Partners
HealthEdge Investment Partners, LLC is an operating-oriented private equity firm founded in 2005 that focuses exclusively on the healthcare industry. HealthEdge seeks to achieve superior returns by investing in businesses that benefit from the knowledge, experience, and network of relationships of its partners. HealthEdge’s partners have more than 100 years of combined operating experience in healthcare as CEOs and investors. For more information on HealthEdge, please visit